Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.53 |
| ▸ | RARA | P10276 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27496466 | 0.86 | MAP2K4 (0.66) | KDM4EMAP2K4RAB9AALDH1A1MAPT | |
| SCHEMBL8126956 | 0.85 | MAPK1 (0.72) | KDM4EMAP2K4RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL8681986 | 0.84 | KDM4E (0.60) | KDM4EMAP2K4RAB9AALDH1A1MAPT | |
| SCHEMBL11903949 | 0.81 | MAP2K4 (0.63) | KDM4EMAP2K4RAB9AALDH1A1MAPK1 | |
| SCHEMBL21802593 | 0.80 | KDM4E (0.56) | KDM4EMAP2K4RAB9AALDH1A1MAPT | |
| SCHEMBL4119529 | 0.80 | ITK (0.62) | KDM4ERAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5386371 | 0.80 | ALOX5 (0.55) | KDM4EMAP2K4RAB9AALDH1A1MAPT | |
| SCHEMBL27956842 | 0.79 | MAP2K4 (0.60) | KDM4EMAP2K4RAB9AALDH1A1MAPK1 | |
| SCHEMBL959364 | 0.79 | KDM4E (1.00) | KDM4ERAB9AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29709972 | 0.79 | KDM4E (1.00) | KDM4ERAB9AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100516049-C | Antiangiogenic agent N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2009-07-22 | — | — | CN | disclosed |
| US-7514465-B2 | Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2009-04-07 | — | — | US | disclosed |
| CN-1962640-A | Novel anti-angiogenic drug N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2007-05-16 | — | — | CN | disclosed |
| EP-1659115-A1 | Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents | Yung Shin Pharm. Ind. Co., Ltd. (TW) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2006-05-18 | — | — | US | disclosed |
| CN-1215060-C | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2005-08-17 | — | — | CN | disclosed |
| CN-1331076-A | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2002-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | FLT4, FLT1, KDR | KDM4E 1210/4885MAP2K4 1359/4885RAB9A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.